| Detected | Trial | Change |
|---|---|---|
| 2026-06-05 | NCT01868451 Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early… |
Trial completed |
| 2026-06-05 | NCT01868451 Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early… |
date change Primary completion moved earlier: 2027-05 -> 2026-06-02 |
| 2026-06-05 | NCT01868451 Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early… |
date change Completion moved earlier: 2027-05 -> 2026-06-02 |
| 2026-05-30 | NCT06743126 SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated… |
Trial sites expanded: 59 -> 66 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06831370 | A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults… | Hodgkin Lymphoma | Recruiting |
| Phase 3 | |||
| NCT03016819 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma… | Alveolar Soft Part Sarcoma | Recruiting |
| NCT04685616 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma | Hodgkin Lymphoma | Recruiting |
| NCT06743126 | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated… | Melanoma, Cutaneous Malignant | Recruiting |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs… | Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | Recruiting |
| NCT06346067 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With… | Advanced or Metastatic NRAS-mutant Melanoma | Active, Not Recruiting |
| NCT03907488 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in… | Ann Arbor Stage III Hodgkin Lymphoma | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT06563245 | Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment | Classical Hodgkin Lymphoma | Recruiting |
| NCT05987332 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic… | Metastatic Uveal Melanoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT06835049 | Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk… | Sarcoma,Soft Tissue | Recruiting |
| NCT06745076 | Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the… | Advanced Hodgkin Lymphoma | Recruiting |
| NCT06377566 | A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | Hodgkin Lymphoma | Recruiting |
| NCT07275216 | Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin… | Classic Hodgkin Lymphoma | Recruiting |
| NCT04067037 | Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced… | Classical Hodgkin Lymphoma | Active, Not Recruiting |
| NCT03407144 | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With… | Hodgkin Lymphoma | Active, Not Recruiting |
| NCT05922904 | PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and… | Hodgkin Lymphoma | Active, Not Recruiting |
| NCT03755804 | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | Hodgkin Lymphoma | Active, Not Recruiting |
| NCT01920932 | Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in… | Stage II Childhood Hodgkin Lymphoma | Active, Not Recruiting |
| NCT05404945 | Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma… | Classical Hodgkin Lymphoma | Active, Not Recruiting |
| NCT07551583 | Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients… | Hodgkin Lymphoma | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT03033914 | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical… | Hodgkin Lymphoma | Active, Not Recruiting |